Literature DB >> 18585543

Life-threatening serotonin toxicity due to a citalopram-fluconazole drug interaction: case reports and discussion.

Tomer T Levin1, Alberto Cortes-Ladino, Mark Weiss, M Lia Palomba.   

Abstract

OBJECTIVE: To discuss two cases of life-threatening serotonin toxicity due to a drug interaction between citalopram and fluconazole and to review the pertinent literature.
METHODS: A Medline search without date limitation was conducted using the terms serotonin syndrome, serotonin toxicity, fluconazole and citalopram. RESULTS AND DISCUSSION: Fluconazole inhibits CYP2C19. Citalopram is a substrate for 2C19 and inhibition of its metabolism may result in serotonin toxicity. Serotonin toxicity in oncology patients may not present with the classic constellation of signs typically described in the literature. Delirium may be the only presenting feature. Current level of evidence for treatment of serotonin toxicity is level 4 or 5 (case series and expert opinion). Nevertheless, there is a strong theoretical basis for treating serotonin toxicity in medical patients with a 5H(2A) blocker such as cyproheptadine.
CONCLUSIONS: Consultation-liaison psychiatrists and oncologists should be aware of this preventable and underrecognized interaction. Citalopram should be stopped or substituted prior to the concurrent administration of fluconazole, and in the event of toxicity, treatment with cyproheptadine has a favorable risk-benefit ratio despite a lack of randomized controlled data to support its use.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18585543     DOI: 10.1016/j.genhosppsych.2008.03.008

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN: 0163-8343            Impact factor:   3.238


  6 in total

Review 1.  [Drug-related delirium in elderly patients].

Authors:  Bernhard Iglseder; Peter Dovjak; Ursula Benvenuti-Falger; Birgit Böhmdorfer; Monika Lechleitner; Ronald Otto; Regina E Roller; Ulrike Sommeregger; Markus Gosch
Journal:  Wien Med Wochenschr       Date:  2010-06

2.  Evaluation of drug interactions in patients treated with antidepressants at a tertiary care cancer center.

Authors:  Lincy Subha Lal; Amy Zhuang; Frank Hung; Chun Feng; Rebecca Arbuckle; Michael J Fisch
Journal:  Support Care Cancer       Date:  2011-04-26       Impact factor: 3.603

Review 3.  Serotonin syndrome.

Authors:  Jacqueline Volpi-Abadie; Adam M Kaye; Alan David Kaye
Journal:  Ochsner J       Date:  2013

4.  Melatonin metabolism in the central nervous system.

Authors:  Rüdiger Hardeland
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

Review 5.  The Serotonin Syndrome: From Molecular Mechanisms to Clinical Practice.

Authors:  James Francescangeli; Kunal Karamchandani; Meghan Powell; Anthony Bonavia
Journal:  Int J Mol Sci       Date:  2019-05-09       Impact factor: 5.923

6.  Identification of a de novo FOXP1 mutation and incidental discovery of inherited genetic variants contributing to a case of autism spectrum disorder and epilepsy.

Authors:  Kristy Jay; Amit Mitra; Taylor Harding; David Matthes; Brian Van Ness
Journal:  Mol Genet Genomic Med       Date:  2019-05-20       Impact factor: 2.183

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.